Plasma posaconazole exposure was assessed in 13 children who underwent a hematopoietic stem cell transplant. The median dosage was 12.5 mg/kg per day, divided into 3 doses. Of these 13 patients, 46.2% (6) and 30.8% (4) achieved concentrations higher than 0.7 and 1.25 mg/L, respectively. In children at high risk, a higher dosage might be needed to achieve target concentrations.
Posaconazole is a broad-spectrum triazole antifungal agent. Its efficacy for the prevention and salvage treatment of invasive fungal infections (IFIs) in high-risk neutropenic adults and hematopoietic stem cell transplant (HSCT) recipients with chronic graft-versus-host disease (GVHD) has been proven [1] [2] [3] .
Target posaconazole levels in plasma have been associated with effective antifungal prophylaxis and treatment. For this reason, therapeutic drug monitoring with target trough concentrations higher than 0.7 and 1.25 mg/L has been suggested for IFI prophylaxis and treatment, respectively [4] .
Although not approved for children younger than 13 years, posaconazole has gained clinical use in pediatrics. Therefore, we sought to assess posaconazole dosages administered in a liquid formulation to children younger than 13 years who had undergone an HSCT and to determine the proportion of these patients who achieved target trough plasma concentrations.
PATIENTS AND METHODS
We identified all children who had undergone an HSCT and were treated at the CHU Sainte-Justine (Montreal, Quebec, Canada) between January 2007 and January 2016. We included children who were younger than 13 years and received posaconazole and for whom at least 1 plasma posaconazole concentration was measured during therapy. Children were identified from databases of the CHU Sainte-Justine pharmacy department and the central referral laboratory. Using a standardized template, we collected demographic (sex and age), clinical (weight, underlying disease, posaconazole doses administered, plasma concentrations of posaconazole, potentially interacting drugs, and clinical outcome), and hepatic function (serum amino transferase level) data.
Posaconazole in suspension (40 mg/mL) was administered orally or via nasogastric tube in combination with a fatty meal or enteral feeding. For all indications, posaconazole dosing was 12 mg/kg per day divided into 3 doses for children who weighted <30 kg and 600 mg/day divided into 3 doses (adult dosing) [2] for those who weighed ≥30 kg.
Posaconazole plasma samples were obtained in the context of therapeutic drug monitoring according to the institution's standard of care. Posaconazole concentrations were measured with a validated high-performance liquid chromatography assay. The lower limit of quantification was 0.078 mg/L [5] .
For each child, only the first posaconazole plasma concentration, obtained 7 or more days after dose initiation, was included in the analysis. Posaconazole is known to exhibit a flat concentration-time profile at steady state, with similar concentrations measured 4, 8, and 12 hours after the dose [6] . Therefore, all posaconazole concentrations, regardless of sampling time after administration, were included in the analysis.
Descriptive statistics are expressed as median, range, or interquartile. Proportions were compared using the χ 2 or Fischer exact test as appropriate. Statistical significance was defined by a P value of <.05.
This retrospective study was approved by the ethical committee of the CHU Sainte-Justine.
RESULTS
Thirteen children (8 girls [61.5%]) were included (Tables 1 and  2 ). The median (range) age was 6.6 years (1.1-12. Ten (76.9%) children received posaconazole as a prophylactic treatment (Table 1 ). These 10 patients received a median dosage of 12.1 mg/kg per day (range, 10.8-19.3 mg/kg per day) divided into 3 doses. Among these children, 5 (50.0%) achieved a trough plasma posaconazole concentration at steady state of greater than 0.7 mg/L, which was defined as the target exposure for prophylaxis. Of these 10 patients, the 2 who received a dosage higher than 15 mg/kg per day achieved plasma concentrations greater than 1.25 mg/L. Three children were treated for an IFI (disseminated aspergillosis [n = 2] or cutaneous mold infection [n = 1]). They received a significantly higher dosage than the patients who received prophylactic treatment (mean, 20.5 mg/kg per day divided into 3 doses; P = .003). Among these 3 patients, 1 achieved a trough plasma concentration greater than 1.25 mg/L, which was defined as the target exposure for IFI treatment (Table 2) .
One child received posaconazole suspension for prophylaxis (dosage, 12.1 mg/kg per day) via nasogastric tube, and the plasma concentration was not detectable. Eight (61.5%) children had mild-to-moderate digestive GVHD at the time their concentration was measured. Gastrointestinal manifestations were the most frequently observed adverse event; vomiting was reported by 38.5% (5 of 13) of the patients. Elevated plasma levels of hepatic transaminases (≥3-fold normal value for age) were observed in 46.2% (6 of 13) of the patients. In 4 cases, interactions with tacrolimus led to the discontinuation of posaconazole. Two patients died as a result of a cause unrelated to IFI.
DISCUSSION
Although posaconazole has been approved for use in adults and children older than 13 years, a dosage has not been defined for younger children. In a retrospective study of 15 children treated with posaconazole as salvage therapy for IFI (median dosage, 21 mg/kg per day), a complete or partial response of the IFI was observed in 60% of the patients [7] . Another study investigated the dosing regimen for children with chronic granulomatous disease and found that, in this specific population, a twice-daily dosing algorithm based on body weight resulted in adequate exposure [8] . More recently, a prospective pharmacokinetics (PK) study was performed in children <13 years of age who received prophylactic posaconazole. A dosage of 120 mg/m 2 per dose 3 times/day (360 mg/kg per day, corresponding to 30 mg/kg per day for 10-kg children and 11 mg/kg per day for 30-kg children) resulted in adequate plasma exposure (mean ± standard deviation trough posaconazole plasma concentration, 0.85 ± 0.56 mg/L) [9] .
In this retrospective study, we observed a high heterogeneity of posaconazole plasma concentrations in our patients who had undergone an HSCT. We also found that with a median daily dosage of 12.5 mg/kg per day divided into 3 doses, in nearly half (46.2%) of the children in our cohort the prophylaxis target (0.7 mg/L) was not reached, and the majority (69.2%) of them had a trough concentration less than the therapeutic target (1.25 mg/L). These results contrast with those of a previous study, despite the fact that the 2 populations of patients seem to have been of similar ages and had similar underlying diseases [9] . Given the high susceptibility and vulnerability of these immunocompromised children to IFI, an optimal plasma posaconazole concentration must be achieved rapidly for effective therapy. These results, therefore, suggest that treatment with a dosage higher than 12.5 mg/kg per day should be initiated, which is consistent with previous literature [7, 8] . Similarly, in another PK study that included 33 children with a median age of 10.5 years (range, 0.5-23.2 years), the authors reported that patients in whom trough concentrations greater than 0.7 mg/L were not reached received lower posaconazole dosages relative to their body weight (median, 12.9 mg/kg per day) [10] . In addition, a PK investigation was conducted among 14 children who received posaconazole at 10 mg/kg body weight divided into 2 doses or 12 mg/kg body weight divided into 3 doses [11] ; a posaconazole plasma concentration greater than 0.7 mg/L was reached in very few children. The median trough posaconazole concentration was higher in those who received posaconazole 3 times/day than in those who received it 2 times/day.
Given the retrospective design of this study, we did not collect time after last dose; because posaconazole was administered in an outpatient setting by the childrens' parents, this information was not available. However, at steady state, posaconazole concentrations are expected to be stable across the dosing interval and to not affect the interpretation of these results [6] .
We did not observe any parameters that could influence posaconazole concentrations. Consistent with our findings, plasma posaconazole concentrations were generally unaffected by demographic variables, including race, sex, body weight, and age [11, 12] . Only food intake has been shown to influence posaconazole bioavailability; posaconazole trough concentrations were 33.5% to 63.5% higher in children who received posaconazole with a fatty meal [11] . In this study, we did not collect any data on feeding. For all patients who receive posaconazole, our pharmacists provide counselling and specify that an oral suspension of posaconazole has to be taken with food, preferably with a high fat content.
One child received the posaconazole suspension via nasogastric tube, and the concentration never reached detectability. It has been shown that lower concentrations are obtained when posaconazole is administered via nasogastric tube [13] . These observations suggest that posaconazole is adsorbed by the nasogastric tube itself and that an oral suspension should not be administered via this route.
No correlation was observed between GVHD, particularly gastrointestinal GVHD, and plasma posaconazole concentrations. This observation is in accordance with that in a previous study, in which plasma posaconazole concentrations were higher among patients with chronic GVHD than among those with acute GVHD [12] . No patient had mucositis at the time their posaconazole concentration was measured.
In agreement with previous reports [7, 11] , gastrointestinal manifestations were the most frequently observed adverse effect. The most severe adverse effect to manage in our cohort was drug interactions, particularly interaction with tacrolimus, which led to discontinuation of posaconazole in 3 children.
Our study was limited by its retrospective design and the small sample size. However, the results suggest that posaconazole dosing higher than 12.5 mg/kg per day might be needed to achieve the target concentration for IFI prophylaxis and treatment in children after an HSCT who are at high risk of IFI. Higher dosing must be validated prospectively.
